Injectable product will treat asthma and rhinosinusitis; application of the medicine should be done every 6 months
The National Health Surveillance Agency published on Monday (May 11, 2026) the registration of a new medicine for the treatment of asthma and chronic rhinosinusitis with severe nasal polyps. Densurko (depemoquimab) is presented as a 100 mg/mL injectable solution, in a pre-filled syringe or applicator pen, ready for use.
The product is indicated as a complementary treatment for asthma in adult and pediatric patients aged 12 years or over with type 2 (allergic) inflammation characterized by excess eosinophils (white blood cells involved in airway inflammation) in the blood.
The condition can cause eosinophilic inflammation and increase the risk of severe asthma attacks. The product must be applied once every 6 months.
Clinical studies demonstrated a statistically significant reduction in the rate of significant exacerbations when compared to placebo, both associated with standard treatment.
RHINOSSINUSITE
In the case of chronic rhinosinusitis with nasal polyps, the medication is only indicated for adult patients in whom conventional therapy (with systemic corticosteroids) and/or surgery does not provide adequate control of the condition.
The disease is a persistent inflammation (lasting more than 12 weeks) of the nasal mucosa and sinuses that is characterized by the growth of benign polyps that block breathing. The recommended dose is the same: one dose every 6 months.
This text was published by Anvisa on May 11, 2026, at 4:03 pm. The content is free for republication, the source is cited, and has been adapted to the standard of Poder360.
